References
References1. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5–S67.NorgrenL]]HiattWR]]DormandyJA&etal;TASC II Working GroupInter-society consensus for the management of peripheral arterial disease (TASC II).J Vasc Surg200745S5-S672. Becker GJ, McClenny TE, Kovacs ME, et al. The importance of increasing public and physician awareness on peripheral artery disease. J Vasc Interv Radiol 2002;13:7–11.BeckerGJ]]McClennyTE]]KovacsME&etal;The importance of increasing public and physician awareness on peripheral artery disease.J Vasc Interv Radiol2002137-113. Murabito JM, D’Agostino RB, Silbershatz H, et al. Intermittent claudication. A risk profile from the Framingham heart study Circulation 1997;96:44–49.MurabitoJM]]D’AgostinoRB]]SilbershatzH&etal;Intermittent claudication. A risk profile from the Framingham heart studyCirculation19979644-494. Reeder BA, Liu L, Horlick L. Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 1996;12:271–275.ReederBA]]LiuL]]HorlickLSociodemographic variation in the prevalence of cardiovascular disease.Can J Cardiol199612271-2755. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510–517.CriquiMH]]FronekA]]Barrett-ConnorE&etal;The prevalence of peripheral arterial disease in a defined population.Circulation198571510-5176. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 2004;110:738–742.SelvinE]]ErlingerTPPrevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000.Circulation2004110738-7427. Colins TC, Peterson NJ, Suarez-Almazor M, et al. The prevalence of peripheral arterial disease in a racially diverse population. Arch Intern Med 2003;163:1469–1474.ColinsTC]]PetersonNJ]]Suarez-AlmazorM&etal;The prevalence of peripheral arterial disease in a racially diverse population.Arch Intern Med20031631469-14748. Gerhard GT, Malinow MR, DeLoughery TG, et al. Higher total homocysteine concentration and lower folate concentrations in premenopausal black women than in premenopausal white women. Am J Clin Nutr 1999;70:252–260.GerhardGT]]MalinowMR]]DeLougheryTG&etal;Higher total homocysteine concentration and lower folate concentrations in premenopausal black women than in premenopausal white women.Am J Clin Nutr199970252-2609. Folsom AR, Wu KK, Conlan MG, et al. Distributions of hemostatic variables in black and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) study. Ethn Dis 1992;2:35–46.FolsomAR]]WuKK]]ConlanMG&etal;Distributions of hemostatic variables in black and whites: population reference values from the Atherosclerosis Risk in Communities (ARIC) study.Ethn Dis1992235-4610. Conlan MG, Folsom AR, Finch A, et al. Associations of Factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost. 1993;70:380–385.ConlanMG]]FolsomAR]]FinchA&etal;Associations of Factor VIII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) study.Thromb Haemost199370380-38511. Fowkes FG, Lee AJ, Hou CM, et al. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risk of peripheral arterial disease and coronary heart disease: Edinburgh artery study. Atherosclerosis 2000;150:179–185.FowkesFG]]LeeAJ]]HouCM&etal;Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risk of peripheral arterial disease and coronary heart disease: Edinburgh artery study.Atherosclerosis2000150179-18512. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs: the Framingham study JAMA 1972;221:661–666.GordonT]]KannelWBPredisposition to atherosclerosis in the head, heart, and legs: the Framingham studyJAMA1972221661-66613. Lu JT, Creager MA. The relationship of cigarette smoking to peripheral arterial disease. Cardiovasc Med 2004;5:189–193.LuJT]]CreagerMAThe relationship of cigarette smoking to peripheral arterial disease.Cardiovasc Med20045189-19314. Beckman J, Creager MA. Management of Peripheral Arterial Disease. London, ReMEDICA publishing, 2000,pp 19–42.BeckmanJ]]CreagerMAManagement of Peripheral Arterial Disease.LondonReMEDICA publishing200019-4215. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epedimiology, pathophysiology, and management. JAMA 2002 287:2570–2581.BeckmanJA]]CreagerMA]]LibbyPDiabetes and atherosclerosis: epedimiology, pathophysiology, and management.JAMA20022872570-258116. Murabito JM, D’ Agostino RB, Silbershatz H, et al. Intermittent claudication: a risk profile from the Framingham heart study. Circulation 1997;96:44–49.MurabitoJM]]D’ AgostinoRB]]SilbershatzH&etal;Intermittent claudication: a risk profile from the Framingham heart study.Circulation19979644-4917. Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham offspring study. Am Heart J 2002;143:961–968.MurabitoJM]]EvansJC]]NietoK&etal;Prevalence and clinical correlates of peripheral arterial disease in the Framingham offspring study.Am Heart J2002143961-96818. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral artery disease: Importance of identifying the population at risk. Vasc Med 1997;2:221–225.CriquiMH]]DenenbergJO]]LangerRD&etal;The epidemiology of peripheral artery disease: Importance of identifying the population at risk.Vasc Med19972221-22519. Greenhalgh RM, Rosengarten DS, Mervart I, et al. Serum lipids and lipoproteins in the peripheral vascular disease. Lancet 1971;2:947–950.GreenhalghRM]]RosengartenDS]]MervartI&etal;Serum lipids and lipoproteins in the peripheral vascular disease.Lancet19712947-95020. Bradby GV, Valente AJ, Walton KW. Serum high-density lipoproteins in peripheral vascular disease. Lancet 1978;2:1271–1274.BradbyGV]]ValenteAJ]]WaltonKWSerum high-density lipoproteins in peripheral vascular disease.Lancet197821271-127421. Smith FB, Lee AJ, Hau CM, et al. Plasma fibrinogen, hemostatic factors and prediction of peripheral arterial disease in Edinburgh artery study. Blood Coagul Fibrinolysis 2000;11:43–50.SmithFB]]LeeAJ]]HauCM&etal;Plasma fibrinogen, hemostatic factors and prediction of peripheral arterial disease in Edinburgh artery study.Blood Coagul Fibrinolysis20001143-5022. Vidula H, Tian L, Liu K, et al. Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study. Ann Intern Med 2008;148:85–93.VidulaH]]TianL]]LiuK&etal;Biomarkers of inflammation and thrombosis as predictors of near-term mortality in patients with peripheral arterial disease: a cohort study.Ann Intern Med200814885-9323. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049–1057.BousheyCJ]]BeresfordSA]]OmennGS&etal;A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.JAMA19952741049-105724. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873–2879.HajjarKAHomocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor.J Clin Invest1993912873-287925. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001;286:1599–1606.McDermottMM]]GreenlandP]]LiuK&etal;Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment.JAMA20012861599-160626. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463–e654.HirschAT]]HaskalZJ]]HertzerNR&etal;ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.Circulation2006113e463-e65427. Mcgee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med 1998;158:1357–1364.McgeeSR]]BoykoEJPhysical examination and chronic lower-extremity ischemia: a critical review.Arch Intern Med19981581357-136428. Criqui MH, Fronek A, Klauber MR, et al. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation 1985;71:516–522.CriquiMH]]FronekA]]KlauberMR&etal;The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population.Circulation198571516-52229. Ouriel K. Peripheral arterial disease. Lancet 2001;358:1257–1264.OurielKPeripheral arterial disease.Lancet20013581257-126430. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 2003;163:884–892.BelchJJ]]TopolEJ]]AgnelliG&etal;Critical issues in peripheral arterial disease detection and management: a call to action.Arch Intern Med2003163884-89231. Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993;270:465–469.VogtMT]]CauleyJA]]NewmanAB&etal;Decreased ankle/arm blood pressure index and mortality in elderly women.JAMA1993270465-46932. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong heart study. Circulation 2004;109:733–739.ResnickHE]]LindsayRS]]McDermottMM&etal;Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong heart study.Circulation2004109733-73933. Darling RC, Raines JK, Brener BJ, et al. Quantitative segmental pulse volume recorder: a clinical tool. Surgery 1972;72:873–877.DarlingRC]]RainesJK]]BrenerBJ&etal;Quantitative segmental pulse volume recorder: a clinical tool.Surgery197272873-87734. Ho KY, de Hann MW, Kessels AG, et al. Peripheral vascular tree stenoses:detection with substracted and nonsubstracted MR angiography. Radiology 1998;206:673–681.HoKY]]de HannMW]]KesselsAG&etal;Peripheral vascular tree stenoses:detection with substracted and nonsubstracted MR angiography.Radiology1998206673-68135. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17:2359–2362.MarckmannP]]SkovL]]RossenK&etal;Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging.J Am Soc Nephrol&NA;172359-236236. Grobner T. Gadolinium, a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104–1108.GrobnerTGadolinium, a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrol Dial Transplant2006211104-110837. Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982;(69 suppl): S24–S26.QuickCR]]CottonLTThe measured effect of stopping smoking on intermittent claudication.Br J Surg1982&NA;S24-S2638. Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987;221:253–260.JonasonT]]BergströmRCessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality.Acta Med Scand1987221253-26039. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;(45 suppl S): S5–S67.NorgrenL]]HiattWR]]DormandyJA&etal;Inter-society consensus for the management of peripheral arterial disease (TASC II).J Vasc Surg2007&NA;S5-S6740. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–986.&NA;The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.N Engl J Med1993329977-98641. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet 1998;352:837–853.&NA;Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group.Lancet1998352837-85342. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559.43. ADVANCE Collaborative Group; Patel M, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–2572.ADVANCE Collaborative GroupPatelM]]MacMahonS]]ChalmersJ&etal;Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.N Engl J Med20083582560-257244. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med 1991;151:1769–1776.RadackK]]DeckCBeta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials.Arch Intern Med19911511769-177645. Thadani U, Whitsett TL. Beta-adrenergic blockers and intermittent claudication. Time for reappraisal. Arch Intern Med 1991;151:1705–1707.ThadaniU]]WhitsettTLBeta-adrenergic blockers and intermittent claudication. Time for reappraisal.Arch Intern Med19911511705-170746. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;2:CD000990.LengGC]]FowlerB]]ErnstEExercise for intermittent claudication.Cochrane Database Syst Rev20002CD00099047. Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006;114:242–248.GargPK]]TianL]]CriquiMH&etal;Physical activity during daily life and mortality in patients with peripheral arterial disease.Circulation2006114242-24848. Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003;38:710–713.WilhiteDB]]ComerotaAJ]]SchmiederFA&etal;Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.J Vasc Surg200338710-71349. Goldhaber SZ, Manson JE, Stampfer MJ, et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study. Lancet 1992;340:143–145.GoldhaberSZ]]MansonJE]]StampferMJ&etal;Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians’ Health Study.Lancet1992340143-14550. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329–1339.&NA;A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). CAPRIE Steering Committee.Lancet19963481329-133951. Reilly MP, Mohler ER III. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001;35:48–56.ReillyMP]]MohlerERIIICilostazol: treatment of intermittent claudication.Ann Pharmacother20013548-5652. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314–1319.ThompsonPD]]ZimetR]]ForbesWP&etal;Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.Am J Cardiol2002901314-131953. Clagett GP, Sobel M, Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:609S–626S.ClagettGP]]SobelM]]JacksonMR&etal;Antithrombotic therapy in peripheral arterial occlusive disease. The seventh ACCP conference on antithrombotic and thrombolytic therapy.Chest2004126609S-626S54. Lehert P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994;23(suppl 3):S48–S52.LehertP]]ComteS]]GamandS&etal;Naftidrofuryl in intermittent claudication: a retrospective analysis.J Cardiovasc Pharmacol199423S48-S5255. Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994;23(suppl 3):S44–S47.MoodyAP]]al-KhaffafHS]]LehertP&etal;An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.J Cardiovasc Pharmacol199423S44-S4756. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999;159:337–345.GirolamiB]]BernardiE]]PrinsMH&etal;Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.Arch Intern Med1999159337-34557. Avellone G, Mandalà V, Pinto A, et al. Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs. Haemostasis 1986;16(suppl 1):55–58.AvelloneG]]MandalàV]]PintoA&etal;Clinical evaluation of short-term defibrotide treatment of patients with atherosclerosis obliterans of the lower limbs.Haemostasis19861655-5858. Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006;48:2539–2545.BrassEP]]AnthonyR]]CobbFR&etal;The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.J Am Coll Cardiol2006482539-254559. Nenci GG, Gresele P, Ferrari G, et al; Mesoglycan Intermittent Claudication group. Treatment of intermittent claudication with mesoglycan—a placebo-controlled, double-blind study. Thromb Haemost 2001;86:1181–1187.NenciGG]]GreseleP]]FerrariG&etal;Mesoglycan Intermittent Claudication groupTreatment of intermittent claudication with mesoglycan—a placebo-controlled, double-blind study.Thromb Haemost2001861181-118760. Takeshita S, Zheung LP, Brogi E, et al. Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest 1994;93:662–670.TakeshitaS]]ZheungLP]]BrogiE&etal;Therapeutic angiogenesis: A single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model.J Clin Invest199493662-67061. Lederman RJ, Mendelsohn FO, Anderson RD, et al; TRAFFIC investigators. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053–2058.LedermanRJ]]MendelsohnFO]]AndersonRD&etal;TRAFFIC investigatorsTherapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial.Lancet20023592053-205862. Rajagopalan S, Mohler ER III, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003;108:1933–1938.RajagopalanS]]MohlerERIII]]LedermanRJ&etal;Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.Circulation20031081933-193863. Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. J Vasc Interv Radiol 1993;4:639–648.WolfGL]]WilsonSE]]CrossAP&etal;Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial.J Vasc Interv Radiol19934639-64864. Gardiner GA Jr, Meyerovitz MF, Stokes KR, et al. Complications of transluminal angioplasty. Radiology 1986;159:201–208.GardinerGAJr]]MeyerovitzMF]]StokesKR&etal;Complications of transluminal angioplasty.Radiology1986159201-20865. Vroegindeweij D, Vos LD, Tielbeek AV, et al. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol 1997;20:420–425.VroegindeweijD]]VosLD]]TielbeekAV&etal;Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study.Cardiovasc Intervent Radiol199720420-42566. Zdanowski Z, Albrechtsson U, Lundin A, et al. Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions. A randomized controlled study. Int Angiol 1999;18:251–255.ZdanowskiZ]]AlbrechtssonU]]LundinA&etal;Percutaneous transluminal angioplasty with or without stenting for femoropopliteal occlusions. A randomized controlled study.Int Angiol199918251-25567. DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000;85:1045–1053.DeBakeyME]]GlaeserDHPatterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up.Am J Cardiol2000851045-1053
